Merus Balance Sheet Health
Financial Health criteria checks 5/6
Merus has a total shareholder equity of $746.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $892.2M and $145.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$787.42m |
Equity | US$746.77m |
Total liabilities | US$145.46m |
Total assets | US$892.23m |
Recent financial health updates
We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely
Sep 20Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans
May 10We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25Recent updates
We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely
Sep 20Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks
Aug 14Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts
Jun 01Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
May 24Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
May 12Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans
May 10Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Mar 01Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 01Merus Stock: Rally Seems Overdone
Jan 23Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?
Jan 14Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)
Dec 18We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price
Jun 20Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate
Feb 08Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Aug 08Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies
Aug 02Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Jun 30Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)
May 14Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)
Mar 03We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts
Aug 08Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)
Jul 28We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Jul 02Financial Position Analysis
Short Term Liabilities: MRUS's short term assets ($806.6M) exceed its short term liabilities ($80.9M).
Long Term Liabilities: MRUS's short term assets ($806.6M) exceed its long term liabilities ($64.6M).
Debt to Equity History and Analysis
Debt Level: MRUS is debt free.
Reducing Debt: MRUS had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MRUS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MRUS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.